As of 2026-02-19, the EV/EBITDA ratio of Summit Therapeutics Inc (SMMT) is -20.14. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SMMT's latest enterprise value is 11,583.15 mil USD. SMMT's TTM EBITDA according to its financial statements is -575.12 mil USD. Dividing these 2 quantities gives us the above SMMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2026-02-18 | -20.14 |
| 2026-02-17 | -19.88 |
| 2026-02-13 | -18.95 |
| 2026-02-12 | -18.52 |
| 2026-02-11 | -19.33 |
| 2026-02-10 | -19.33 |
| 2026-02-09 | -18.96 |
| 2026-02-06 | -18.99 |
| 2026-02-05 | -17.51 |
| 2026-02-04 | -18.25 |
| 2026-02-03 | -18.47 |
| 2026-02-02 | -17.78 |
| 2026-01-30 | -18.33 |
| 2026-01-29 | -19.52 |
| 2026-01-28 | -19.83 |
| 2026-01-27 | -20.17 |
| 2026-01-26 | -21.02 |
| 2026-01-23 | -20.93 |
| 2026-01-22 | -22.07 |
| 2026-01-21 | -21.40 |
| 2026-01-20 | -20.37 |
| 2026-01-16 | -21.64 |
| 2026-01-15 | -21.94 |
| 2026-01-14 | -22.43 |
| 2026-01-13 | -21.34 |
| 2026-01-12 | -21.64 |
| 2026-01-09 | -25.06 |
| 2026-01-08 | -23.96 |
| 2026-01-07 | -24.19 |
| 2026-01-06 | -23.74 |
| 2026-01-05 | -22.16 |
| 2026-01-02 | -22.26 |
| 2025-12-31 | -22.22 |
| 2025-12-30 | -22.22 |
| 2025-12-29 | -22.60 |
| 2025-12-26 | -23.07 |
| 2025-12-24 | -23.38 |
| 2025-12-23 | -23.04 |
| 2025-12-22 | -23.08 |
| 2025-12-19 | -22.65 |
| 2025-12-18 | -21.64 |
| 2025-12-17 | -21.60 |
| 2025-12-16 | -21.89 |
| 2025-12-15 | -22.08 |
| 2025-12-12 | -22.33 |
| 2025-12-11 | -22.87 |
| 2025-12-10 | -22.81 |
| 2025-12-09 | -21.62 |
| 2025-12-08 | -23.69 |
| 2025-12-05 | -23.29 |